Printer Friendly

SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES

 PALO ALTO, Calif., March 31 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX), today announced the publication of two articles appearing in leading scientific journals during the first quarter of 1993. Both papers showed that the severe combined immunodeficient (SCID) mouse, when implanted with human organs, serves as a valuable research tool and drug testing surrogate for human subjects. The SCID-hu mouse further enables SyStemix scientists to study the pathogenic mechanisms of disease such as HIV and cancer metastasis.
 "The publication of these articles further demonstrates not only the value of the SCID-hu mouse to scientific research, but its ability to be used in a broad spectrum of development and preclinical studies," said Linda Sonntag, Ph.D., president and CEO of SyStemix. "We are currently using the mouse to study chemotherapies for AIDS, gene therapy of AIDS and cellular therapies as adjuncts for cancer chemotherapy. In addition, this model is also useful in studying organ transplantation."
 In the March 15 issue of Blood, SyStemix scientists reported new data supporting that the company's proprietary SCID-hu mouse provides a useful and unique preclinical model to assess the in vivo effects of human hematopoietic growth factors as novel therapeutics for the human blood forming system, otherwise known as the hematopoietic system.
 The results obtained from SCID-hu mice treated by single administration of human recombinant G-CSF, IL-3 or IL-6 are consistent with results reported from human clinical trials. These hematopoietic growth factors are already proving their usefulness in the treatment of bone marrow failure caused by chemotherapy, radiotherapy and various hematopoietic disorders.
 The authors of the paper are Seishi Kyoizumi, Ph.D., Lesley J. Murray, Ph.D., and Reiki Namikawa, M.D., Ph.D.
 In the January issue of the Proceedings of the National Academy of Sciences, SyStemix scientists found that the SCID-hu mouse serves as a valuable animal model for studying the pathogenesis of cytomegalovirus (CMV) infection and also for evaluating the effects of antiviral drugs.
 CMV is a virus that is found only in humans but results showed that SCID-hu mice supported replication of the virus. Furthermore, treatment of infected animals with ganciclovir reduced viral replication as it does in humans, thereby demonstrating the value of the SCID-hu system for evaluating antiviral therapies.
 The authors of the paper are Edward S. Mocarski, Ph.D., Mark Bonyhadi, Ph.D., Suzan Salimi, Joseph M. McCune, M.D., Ph.D., and Hideto Kaneshima, M.D., Ph.D.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and maegkaryocyte progenitors.
 -0- 3/31/93
 /CONTACT: Linda Sonntag, Ph.D., president and CEO of SyStemix, 415-813-6510; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for SyStemix/
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU:

GK-OS -- NY024 -- 1454 03/31/93 11:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:473
Previous Article:CUSTOMERS ADVOCATE AS/400 AS CLIENT SERVER OF CHOICE
Next Article:IBM AND HYPERTEC ENTER AGREEMENT
Topics:


Related Articles
SANDOZ LTD. TO ACQUIRE 60 PERCENT OF SYSTEMIX COMMON STOCK
SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
SYSTEMIX DISCOVERY OF PLURIPOTENT STEM CELLS NAMED ONE TOP 10 MEDICAL ADVANCES OF 1992
SYSTEMIX ENTERS JOINT VENTURE WITH SANDOZ FOR GENE THERAPY AGAINST HIV
SYSTEMIX REPORTS HIV FINDING IN 'NATURE'
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX PRESIDENT/CEO RESIGNS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY
Novartis to Optimize Cell and Gene Therapy R&D

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters